(19)
(11) EP 2 794 593 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.05.2017 Bulletin 2017/18

(45) Mention of the grant of the patent:
01.02.2017 Bulletin 2017/05

(21) Application number: 12812248.8

(22) Date of filing: 20.12.2012
(51) International Patent Classification (IPC): 
C07D 401/12(2006.01)
C07D 405/14(2006.01)
C07D 417/14(2006.01)
A61K 31/4427(2006.01)
A61P 3/04(2006.01)
 C07D 401/14(2006.01)
C07D 413/14(2006.01)
A61K 31/506(2006.01)
A61K 31/4725(2006.01)
A61P 25/18(2006.01)
(86) International application number:
PCT/EP2012/076447
(87) International publication number:
WO 2013/092893 (27.06.2013 Gazette 2013/26)

(54)

SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS

SPIRO-AMINOVERBINDUNGEN ALS OREXIN-ANTAGONISTEN

COMPOSÉS SPIRO-AMINOFONCTIONNELS COMME ANTAGONISTES D'OREXIN

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 21.12.2011 IT MI20112329

(43) Date of publication of application:
29.10.2014 Bulletin 2014/44

(73) Proprietor: Rottapharm Biotech S.r.l.
20900 Monza (MB) (IT)

(72) Inventors:
  • STASI, Luigi Piero
    20900 Monza (MB) (IT)
  • ROVATI, Lucio Claudio
    20900 Monza (MB) (IT)
  • ARTUSI, Roberto
    20900 Monza (MB) (IT)
  • COLACE, Fabrizio
    20900 Monza (MB) (IT)
  • MANDELLI, Stefano
    20900 Monza (MB) (IT)
  • PERUGINI, Lorenzo
    20900 Monza (MB) (IT)

(74) Representative: Rambelli, Paolo et al
Jacobacci & Partners S.p.A. Corso Emilia 8
10152 Torino
10152 Torino (IT)


(56) References cited: : 
EP-A1- 2 275 421
 WO-A1-2011/006960
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).